Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures biology, today announced the closing of an oversubscribed $26 million financing round to enable the development of fit-for-purpose solutions leveraging 10-color capabilities to support cell and gene therapy, minimal residual disease testing (MRD), biomarker validation, vaccine quality control, and other applications. Led by ARCH Venture Partners with participation from F-Prime Capital and Primer Ventures, the funding round will also support the company’s global commercial expansion under the leadership of newly appointed Vice President of Global Sales, Christopher Citraro.
“2026 is a critical year for Countable Labs’ momentum. This financing gives us the resources to ensure every laboratory that could benefit from a more sensitive genomics measurement solution finds Countable PCR,” said Giovanna Prout, Chief Executive Officer at Countable Labs. “Our initial studies with clinical samples and use cases validated the technology’s robustness. Now we must develop and globally market new products for key customer segments, such as cell and gene therapy and MRD, where labs need easy-to-use precision measurement solutions that go beyond the capabilities of digital PCR.”
Countable PCR is a highly scalable single-molecule quantification technology delivering superior sensitivity and precision to digital PCR, with no Poisson correction, no standard curves, and no ambiguity. Purpose-built for diverse applications across research, translational science, and industrial testing, Countable PCR offers unique capabilities including molecular linkage, a critical way to understand patterns of heredity and regions of the genome associated with disease. Delivering simplicity, throughput, broad dynamic range, and multiplexing, Countable PCR is the ideal tool for laboratories looking to detect rare events, fusions, and markers of genome integrity across a wide range of sample inputs.
“PCR technology is widespread, but ready for disruption from faster, less expensive, and more robust technologies that remove the ambiguity that has plagued the industry,” said Corey Ritter, Partner at ARCH Venture Partners. “Countable Labs has completely reimagined PCR, creating a highly accurate, user-friendly solution ideal for distributed use across research, translational research, and industrial testing. These attributes position the company for long-term growth and success.”
“Through our investment in Countable Labs, we aim to democratize access to new genomic tools, helping to bring rare event detection capabilities to customers around the world,” said Robert Weisskoff, Ph.D., Senior Partner at F-Prime Capital. “From minimal residual disease testing to cell and gene therapy manufacturing to pathogen tracking, Countable PCR has the power and robustness to overtake many segments where digital PCR and next-generation sequencing currently dominate.”
Chris Citraro to Lead Global Sales
Chris Citraro joins Countable Labs as Vice President, Global Sales with nearly 20 years experience selling leading innovative life sciences tools. He joins the company from 10x Genomics where he’s held leadership roles in regional and biopharma sales. Prior to 10x Genomics, he held sales roles at Agena Biosciences, Life Technologies/Thermo Fisher Scientific, and MP Biomedicals. He holds a B.S. in biological sciences from Ohio University.
“The future of genomic testing requires technologies that are simple, sensitive, and inexpensive, helping to democratize access to genomic diagnostics, and high-volume genome-based clinical and industrial testing,” said Christopher Citraro, Vice President of Global Sales at Countable Labs. “Countable PCR is exactly that, a technological step change that bridges the gap between complex digital PCR and the discoveries of next-generation sequencing, delivering clear, unambiguous results at scale.”
About Countable Labs
Countable Labs is transforming how biology is measured— bringing single-molecule precision to cell and gene therapy, oncology, molecular diagnostics, and other applications that demand the highest analytical performance. Countable PCR delivers at least 10 times the sensitivity of conventional PCR, with dynamic range and quantitative accuracy that existing digital PCR and next-generation sequencing approaches have not achieved — enabling detection and quantification of rare targets with a level of confidence that fundamentally changes what’s measurable. Founded in 2019 and headquartered in Palo Alto, Calif., Countable Labs is privately held and backed by ARCH Venture Partners, F-Prime Capital, and Premier Ventures. Visit www.countablelabs.com to learn more or follow the company on LinkedIn or YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260528682954/en/
Media gallery
